Sulfasalazine to Bridge a Nine-Month Wait, in a Patient With No Peripheral Disease to Treat
A positive latent tuberculosis test just pushed her first biologic back by months. Reaching for sulfasalazine in the meantime looks like doing something rather than nothing — except the newest guideline specifically excludes her exact disease pattern from that drug's evidence base.
Aisha B. spent the last year of her ecology graduate program doing fieldwork in a region with high tuberculosis prevalence, collecting soil samples for a dissertation chapter she finished the week before her inflammatory back pain finally got bad enough to see a rheumatologist. The workup that followed found her clinical picture convincing — morning stiffness over an hour, alternating buttock pain, real improvement with exercise and NSAIDs, HLA-B27 positive — but her sacroiliac MRI showed no active inflammation and her CRP has stayed normal on two separate draws, placing her disease on the non-radiographic side of axSpA without the objective inflammatory findings biologic eligibility is usually built around. That question became secondary the moment her pre-biologic tuberculosis screening came back positive: a QuantiFERON-confirmed latent infection with no evidence of active disease, given the well-documented risk of reactivation under either mechanism. Consensus practice, the ACR's included, puts the threshold at roughly a month of latent-TB therapy before a biologic starts, not course completion. Her negative screen before she left, against a positive one on return, dates the conversion to that year of fieldwork — and recent infection is where progression risk concentrates. With no objective inflammatory findings to argue urgency against it, a four-week wait became a nine-month one.
Nine months is a long time to tell a 24-year-old in daily pain that nothing new is coming. The instinct in the room, once the TB-treatment timeline was clear, was to reach for something — and sulfasalazine, an old, familiar, non-biologic option, was the obvious candidate. It is also, under the newest guideline, explicitly not that candidate: the 2026 ACR/SAA/SPARTAN update advises against conventional synthetic DMARDs unless peripheral arthritis or extra-musculoskeletal manifestations are present, a restriction grounded in a genuine and long-standing evidence gap — sulfasalazine trials in ankylosing spondylitis have shown benefit concentrated in peripheral joint symptoms, never convincingly in the axial disease that is the entirety of what Aisha actually has. She has taken the delay better than most of her care team expected, by her own account, and the pain itself hasn't changed, nor has the fatigue that's made finishing her dissertation edits harder than she'd like to admit. What is worth stating plainly is that the length of her wait is not being set by a rule about tuberculosis; a rule would have released her at four weeks. It is being set by her recent exposure on one side and her normal CRP and quiet MRI on the other — which means the thing keeping her off a biologic is the same thing that would have made her a marginal candidate for one anyway.
Nine months with nothing new to give her
I understand the impulse to reach for sulfasalazine while we wait, but I don't think it survives contact with what the drug actually does. Every controlled trial of sulfasalazine in ankylosing spondylitis that showed real benefit showed it in peripheral joint symptoms — it has never convincingly moved axial disease on its own. She has no peripheral arthritis, no enthesitis, no dactylitis. Starting it wouldn't bridge her axial disease; it would just be a drug with no matched mechanism for the disease she actually has.
Before we plan around a nine-month wait, I want to be clear it isn't a rule I'm applying — it's a judgment I'm making about her. The standard threshold most guidance settles on is about four weeks of isoniazid before a TNF or IL-17 inhibitor starts; the full course is not required first. I'd go longer here specifically because her conversion looks recent after a year in a high-prevalence region, and recent infection is where progression risk concentrates. If she had a raging CRP and a hot MRI I would take the four weeks and accept the risk. She doesn't, so I'm not trading much for the caution. Meanwhile the window isn't empty: baseline and monthly liver function monitoring, an explicit conversation about anything else hepatically cleared going on top of it, and an adherence plan for a genuinely long regimen. That's the actual clinical work of this window, even though it isn't a rheumatology drug.
Adding sulfasalazine on top, specifically, would mean asking her liver to tolerate a second agent with its own monitoring requirements during a course where we're already watching transaminases closely — a real cost for a drug we don't even expect to help her spine.
Agreed on both counts, but I want to make sure "not sulfasalazine" doesn't quietly become "nothing more to offer her." Her NSAID trial is partial, not maximized on timing — a scheduled, not as-needed, dosing pattern often does better in axial disease specifically. A physical therapy referral for a spondyloarthritis-specific exercise program has real, trial-supported benefit independent of any drug. And we should set an actual date to reassess her MRI and CRP once the isoniazid course is further along, so the nine months has a concrete endpoint rather than an open-ended wait.
Agreed: scheduled naproxen, isoniazid with monthly liver-function monitoring, a physical therapy referral for a spondyloarthritis-specific program, and a fixed re-evaluation date at month six of the TB course to reassess MRI/CRP and plan for biologic initiation.
Not agreed, and named explicitly rather than resolved: whether the extra eight months beyond the standard four-week threshold are actually buying enough risk reduction to justify themselves, and how much a persistently normal CRP and quiet MRI at month six should count against starting a biologic at all. The rheumatologist would proceed to a TNF inhibitor on clinical grounds alone once the TB course finishes; the infectious disease physician would prefer confirming treatment completion with an interim clinical check before any immunosuppressive therapy starts, given how recently she returned from a high-prevalence region.